IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Attorney Docket No.: LFCTP001X3US

Thomas W. Konowalchuk Examiner: Hui, San Ming R.

Application No.: 10/016,282 Group: 1617

Filed: December 6, 2001 Confirmation No.: 4202

Title: METHODS FOR PREVENTING

LESIONS CAUSED BY VIRUSES OF

THE HERPESVIRIDAE OR POXVIRIDAE FAMILY

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that this correspondence is being transmitted electronically through EFS-WEB on January 13, 2009 to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-

1450.

Signed: /Carol Mendel/

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR §§ 1.56 AND 1.97(c))

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The references listed in the attached PTO Form 1449 may be material to examination of the above-identified patent application. Applicants submit a list of the identified references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make the identified references of official record in this application. The above-identified application is a Continuation-in-part of prior application U.S. Patent Application No. 09/795,279, now U.S. Patent No. 7,399,790. Because some of the listed references were either cited by the USPTO, or submitted to the USPTO in the prior application, under 37 CFR § 1.98(d), Applicants submit that copies of these references need not be provided. Copies of non-U.S. references that were not cited in the priority application are attached.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this reference indeed constitutes prior art.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits, or after three months from the filing date of this application, whichever event occurred last, but it is believed before the mailing date of either: (i) a final action under §1.113 or (ii) a notice of allowance under §1.311, whichever occurs first.

Accompanying this Information Disclosure Statement is the fee set forth in 37 CFR 1.17(p).

Authorization for Deposit Account

In view of the foregoing, the Commissioner is hereby authorized to charge the \$180 Information Disclosure Fee, and if deemed necessary, any additional fee due in conjunction with the filing of this Information Disclosure Statement to our Deposit Account Number 504480 (Order No. LFCTP001X3US).

Respectfully submitted, Weaver Austin Villeneuve & Sampson LLP

/Tom Hunter/

Tom Hunter Registration No. 38,498

P.O. Box 70250 Oakland, CA 94612-0250